The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
The rat protein quantified as “Serine/threonine-protein kinase A‑Raf (A‑Raf)” in a rat retinal proteomics dataset is explicitly annotated with UniProt accession P14056, confirming that P14056 corresponds to rat Araf/A‑Raf (Rattus norvegicus). (kwong2021differentialretinalprotein pages 9-11)
Araf encodes a RAF-family serine/threonine kinase that functions as an upstream node in the canonical RAS→RAF→MEK→ERK MAPK cascade. In this pathway, activated RAS (RAS‑GTP) engages RAF kinases (ARAF/BRAF/CRAF/RAF1), enabling RAF activation and downstream MEK and ERK phosphorylation. (spencersmith2024regulationofraf pages 1-3, bahar2023targetingtherasrafmapk pages 1-2)
A recent RAF regulation review (2024) describes RAFs as composed of an N‑terminal regulatory (REG) region and a C‑terminal catalytic (CAT) region. The REG region includes a RAS-binding domain (RBD) and a cysteine-rich domain (CRD; zinc-finger) that supports membrane interactions and contributes to autoinhibition; the CAT region contains the kinase domain and tail. (spencersmith2024regulationofraf pages 1-3)
A core feature of RAF activation is a regulated transition from an autoinhibited monomeric state to an active dimeric state. In resting cells, RAFs are commonly described as inactive cytosolic monomers; upon RAS activation they become recruited to membranes and form active dimers. (spencersmith2024regulationofraf pages 1-3)
A defining regulatory element is 14‑3‑3 binding: RAFs have two high-affinity phosphoserine docking sites (N0 in the REG/S/T-rich region and C0 in the C‑terminal tail) that engage obligate dimeric 14‑3‑3 proteins; this interaction can help stabilize autoinhibition and, in activated states, stabilize active dimers (bridge C0 sites). (spencersmith2024regulationofraf pages 1-3)
The domain organization and an activation-cycle schematic are shown in cropped figures from Spencer‑Smith & Morrison (2024). (spencersmith2024regulationofraf media 4220244e, spencersmith2024regulationofraf media 1fe62c33)
At the pathway level, RAF kinases act as MEK kinases, phosphorylating/activating MEK1/2, which then phosphorylates ERK to drive transcriptional programs. (adamopoulos2024rafandmek pages 2-4)
However, multiple sources emphasize that A‑Raf has comparatively low MEK kinase activity relative to B‑Raf; e.g., A‑Raf is described as a poor MEK kinase (partly attributed to N‑region sequence divergence) and weakly activated by certain oncogenic stimuli in some contexts. (rauch2016differentiallocalizationof pages 1-2, su2022arafproteinkinase pages 3-5)
A‑Raf can also act through non-catalytic mechanisms. In epithelial differentiation contexts, A‑Raf is described as binding MST2 and suppressing MST2-mediated apoptosis, indicating kinase-independent pathway crosstalk. (rauch2016differentiallocalizationof pages 1-2)
A more recent mechanistic study demonstrates another kinase-independent function: ARAF can increase RAS‑GTP by antagonizing NF1 (a RasGAP) binding to RAS, thereby reducing NF1-stimulated GTP hydrolysis. (su2022arafproteinkinase pages 7-8)
RAF family members are described as cytosolic in the inactive state and recruited to the plasma membrane upon RAS‑GTP engagement as part of activation. (spencersmith2024regulationofraf pages 1-3)
Beyond the canonical cytosol↔plasma membrane cycle, A‑Raf has been reported to localize to mitochondria (together with MST2) in tumor contexts; conversely, in proliferating normal basal epithelial cells, A‑Raf is described as cytosolic and redistributed to the plasma membrane during differentiation, with KSR2 implicated in redistribution. (rauch2016differentiallocalizationof pages 1-2)
Important limitation for rat functional annotation: none of the rat-specific expression/proteomics studies retrieved here provide direct rat tissue subcellular localization for A‑Raf; thus mitochondrial/plasma-membrane localization is best treated as inference for the rat ortholog based on conserved RAF biology and ARAF studies in other vertebrate systems. (rauch2016differentiallocalizationof pages 1-2, spencersmith2024regulationofraf pages 1-3, kwong2021differentialretinalprotein pages 9-11)
In a rat partial hepatectomy model, A‑raf‑1 mRNA is transiently induced during liver regeneration. Northern blot quantification reported ~2.5‑fold induction at 12 h and a peak around 18–24 h, with one reported 24 h value of 4.7‑fold for A‑raf‑1 (whole liver) and return to basal by ~72 h. In isolated hepatocytes at 24 h, A‑raf‑1 mRNA increased ~3.9‑fold. (silverman1989expressionofc‐raf‐1 pages 1-2, silverman1989expressionofc‐raf‐1 pages 2-3)
These data support a role for Araf in early regenerative programs that are temporally correlated with growth signaling and cell-cycle entry in hepatocytes, although the work does not directly establish a causal mechanism. (silverman1989expressionofc‐raf‐1 pages 1-2)
A rat brain LC‑MS/MS study analyzing insulin-signaling related proteomic changes reported that ARAF (P14056) abundance was downregulated at day 60 of phenobarbital treatment with fold change 0.760885 versus control (and was not emphasized as altered at day 90). (wang2020alterationsofglucose pages 6-7)
This provides rat in vivo evidence that A‑Raf protein abundance is regulated in brain under chronic pharmacologic stress, though the pathway linkage (insulin/MAPK crosstalk) is not mechanistically resolved in the excerpt. (wang2020alterationsofglucose pages 6-7)
In rat retina two weeks after partial optic nerve transection, integrated SWATH and targeted MRM proteomics quantified A‑Raf (P14056) as upregulated in the temporal quadrant with ratio 1.55, log2FC ~0.63, p = 0.04. (kwong2021differentialretinalprotein pages 9-11)
This implicates A‑Raf protein regulation in retinal responses to injury/degeneration, consistent with broad RAF/MAPK roles in survival and stress signaling, though it does not specify the causal pathway node (e.g., MEK/ERK vs non-catalytic functions). (kwong2021differentialretinalprotein pages 9-11)
A 2024 expert review highlights that recent cryo‑EM/structural studies have provided “snapshots” of RAF regulatory states (e.g., autoinhibited BRAF monomer; active BRAF/CRAF dimers; HSP90/CDC37 complexes) and emphasizes central roles for CRD-mediated autoinhibition, 14‑3‑3 dimers, and phosphatase/chaperone systems (PP5; HSP90/CDC37) in RAF regulation. The review explicitly notes the current lack of solved structures for ARAF and calls for additional structural and live-cell studies. (spencersmith2024regulationofraf pages 1-3, spencersmith2024regulationofraf pages 6-7)
A 2023 high-impact review summarizes the therapeutic landscape of RAF/MAPK targeting, emphasizing that RAF inhibitor (RAFi) + MEK inhibitor combinations are clinically validated but commonly limited by pathway reactivation and resistance, with autophagy discussed as a contributor to RAFi resistance and a potential combinatorial target. (bahar2023targetingtherasrafmapk pages 1-2)
A 2024 NSCLC-focused review further delineates RAF inhibitor classes, including monomer-selective RAF inhibitors that can yield paradoxical MAPK activation in BRAF-wild-type settings, and discusses the development of next-generation dimer/equipotent RAF inhibitors and combination regimens. (adamopoulos2024rafandmek pages 2-4)
Although not 2023–2024, a mechanistic Molecular Cell paper (2022) provides a major shift in how ARAF can function: it shows ARAF can promote RAS activation (RAS‑GTP accumulation) by competing with NF1, requiring ARAF’s RAS-binding capacity and unique N-terminus but not dimerization or kinase activity. This supports the view that ARAF may act as a regulator of the RAS node in addition to acting downstream of RAS as a MEK kinase. (su2022arafproteinkinase pages 7-8)
In clinical oncology, RAF/MEK inhibitors primarily target oncogenic activation of the RAS–RAF–MEK–ERK axis (most often via BRAF alterations). In BRAFV600E NSCLC, FDA approvals include dabrafenib + trametinib (2017) and encorafenib + binimetinib (2023). (adamopoulos2024rafandmek pages 1-2)
Because these applications are driven largely by BRAF-mutant disease biology, they are directly relevant to RAF pathway pharmacology but only indirectly informative about rat Araf (P14056) physiological roles. (adamopoulos2024rafandmek pages 1-2, bahar2023targetingtherasrafmapk pages 1-2)
Current real-world use of RAF/MEK combinations is illustrated by multiple recruiting trials and surveillance studies, including:
For functional annotation of rat Araf (P14056), the strongest cross-source consensus is:
Given conserved RAF regulation, rat A‑Raf is expected to cycle between cytosol and plasma membrane depending on RAS activation status, with possible context-dependent mitochondrial localization inferred from non-rat studies. (spencersmith2024regulationofraf pages 1-3, rauch2016differentiallocalizationof pages 1-2)
The rat studies provide concrete tissue and perturbation contexts where A‑Raf expression/abundance changes:
These collectively support that rat Araf is dynamically regulated in vivo across proliferative, stress, and injury contexts, aligning with MAPK pathway biology. (kwong2021differentialretinalprotein pages 9-11, silverman1989expressionofc‐raf‐1 pages 1-2)
The following table consolidates rat-specific evidence plus mechanistic and clinical context (with publication dates and URLs).
| Evidence type | System/tissue/model | Key finding (include quantitative values) | Method | Species | Citation context ID | Publication year | URL |
|---|---|---|---|---|---|---|---|
| mRNA | Regenerating liver after 70% partial hepatectomy; isolated hepatocytes | A-raf-1 mRNA increased transiently during rat liver regeneration: ~2.5-fold at 12 h, maximal ~18–24 h; reported 24 h values include 4.7-fold increase for A-raf-1 in whole liver, with return to basal by 72 h. In isolated hepatocytes at 24 h, A-raf-1 mRNA increased ~3.9-fold. Transcript size reported as 2.4 kb. | Northern blot autoradiography of total/cytoplasmic RNA, probe hybridization, densitometry normalized to albumin | Rat (Rattus norvegicus) | (silverman1989expressionofc‐raf‐1 pages 2-3, silverman1989expressionofc‐raf‐1 pages 1-2) | 1989 | https://doi.org/10.1002/mc.2940020203 |
| protein | Brain tissue from phenobarbital-addictive rats | ARAF protein (UniProt P14056) was downregulated at day 60 after chronic phenobarbital treatment with reported fold change 0.760885 vs control; not highlighted as significantly altered at day 90. | LC-MS/MS proteomics | Rat (Rattus norvegicus) | (wang2020alterationsofglucose pages 6-7) | 2020 | https://doi.org/10.1021/acs.jproteome.0c00703 |
| protein | Retina, temporal quadrant, 2 weeks after partial optic nerve transection (pONT) | A-Raf protein (accession P14056) was upregulated with ratio 1.55, log2FC ~0.63, p = 0.04 in the temporal quadrant. Quantification was supported by SWATH-MS and targeted MRM-MS; temporal quadrant platform concordance R² = 0.965. | SWATH-MS discovery proteomics with MRM-MS validation | Rat (Rattus norvegicus) | (kwong2021differentialretinalprotein pages 9-11) | 2021 | https://doi.org/10.3390/ijms22168592 |
| mechanism | RAF family signaling context relevant to rat Araf/P14056 | RAFs (ARAF, BRAF, CRAF) are RAS effectors that phosphorylate MEK, initiating the MEK→ERK cascade. In resting cells RAFs are cytosolic inactive monomers; after RAS-GTP binding they are recruited to membrane and form active dimers. ARAF/CRAF have lower basal kinase activity than BRAF. Domain organization includes RBD, CRD, S/T-rich region, kinase domain, with N0/C0 14-3-3 docking sites. | Structural/biochemical review | Vertebrate RAF family (not rat-specific experiment) | (spencersmith2024regulationofraf pages 1-3, spencersmith2024regulationofraf pages 6-7) | 2024 | https://doi.org/10.1042/bst20230552 |
| mechanism | ARAF-specific signaling mechanism | ARAF can increase RAS-GTP by antagonizing NF1 binding to RAS. NF1 catalytic fragment stimulated RAS GTP hydrolysis with EC50 ~2 μg/ml for H-/N-RAS and ~20 μg/ml for KRAS; GAP domains increased intrinsic hydrolysis by ~105-fold. ARAF overexpression reduced NF1-RAS association by ~50% and increased RAS-GTP; similar effects with BRAF/CRAF required much higher overexpression (15–30-fold vs 4–6-fold for ARAF). This effect required RAS binding and ARAF’s unique N-terminus, but not dimerization or kinase activity. | In vitro GTPase-Glo biochemistry; cell-based overexpression/knockdown | Human/mouse systems (mechanistic inference for rat ortholog) | (su2022arafproteinkinase pages 7-8, su2022arafproteinkinase pages 3-5) | 2022 | https://doi.org/10.1016/j.molcel.2022.04.034 |
| review/localization | Epithelial differentiation and apoptosis studies | A-Raf is a weak MEK kinase and also has kinase-independent functions, including binding MST2 to suppress apoptosis. Localization is dynamic: A-Raf/MST2 localize to mitochondria in tumor cell lines and primary tumors; in proliferating normal basal epithelial cells A-Raf is cytosolic and moves to the plasma membrane during differentiation. | Cell biology/mechanistic study | Mainly human cell/tumor systems | (rauch2016differentiallocalizationof pages 1-2) | 2016 | https://doi.org/10.1038/cdd.2016.2 |
| review | Cancer signaling and therapeutic landscape | The RAS/RAF/MAPK pathway is a major oncogenic signaling axis; RAF inhibitors combined with MEK inhibitors are approved for RAF-mutant cancers. Reported efficacy/resistance figures include tumor shrinkage in >90% of patients with dabrafenib in cited settings, with ~50% partial/complete responses, and clinical resistance to RAF inhibitors emerging in about 6–7 months. | Narrative review of mechanistic and clinical literature | Human clinical oncology | (bahar2023targetingtherasrafmapk pages 1-2, bahar2023targetingtherasrafmapk pages 16-17) | 2023 | https://doi.org/10.1038/s41392-023-01705-z |
| review/clinical | NSCLC and RAF/MEK inhibitor implementation | In NSCLC, BRAF V600E occurs in ~4% of cases; NSCLC accounts for ~85% of lung cancers. Epidemiology cited includes 18% of cancer deaths worldwide attributed to lung cancer and 125,070 US deaths in 2024. Approved BRAF–MEK combinations for BRAFV600E-mutant NSCLC include dabrafenib + trametinib (2017) and encorafenib + binimetinib (2023). Pathway alterations overall drive ~30% of cancers; NSCLC mutation prevalences cited include KRAS 25% and BRAF 3–5%. | Clinical/translational review | Human clinical oncology | (adamopoulos2024rafandmek pages 1-2, adamopoulos2024rafandmek pages 2-4, adamopoulos2024rafandmek pages 4-5) | 2024 | https://doi.org/10.3390/ijms25094633 |
| DB | Disease-target association database | Open Targets lists ARAF associations with cancer (score 0.6619), hypertrophic cardiomyopathy (0.5845), Costello syndrome (0.5409), Noonan syndrome (0.5409), and low grade glioma (0.4973). These are disease-association data for human ARAF, useful for translational context but not rat-specific functional evidence. | Open Targets integrated evidence | Human target-disease associations | (OpenTargets Search: -ARAF) | 2024 access | https://platform.opentargets.org/ |
Table: This table summarizes the most relevant evidence gathered for rat Araf (UniProt P14056), integrating rat-specific mRNA/protein studies with mechanistic and clinical-context sources needed for functional annotation. It highlights where direct rat evidence exists and where inference comes from broader ARAF/RAF-family literature.
Open Targets lists ARAF associations with multiple human diseases (e.g., cancer; cardiomyopathy; RASopathies), which is useful for translational context but should not be treated as rat-specific functional evidence. (OpenTargets Search: -ARAF)
References
(kwong2021differentialretinalprotein pages 9-11): Jacky M. K. Kwong, Joseph Caprioli, Ying H. Sze, Feng J. Yu, King K. Li, Chi H. To, and Thomas C. Lam. Differential retinal protein expression in primary and secondary retinal ganglion cell degeneration identified by integrated swath and target-based proteomics. International Journal of Molecular Sciences, 22:8592, Aug 2021. URL: https://doi.org/10.3390/ijms22168592, doi:10.3390/ijms22168592. This article has 9 citations.
(spencersmith2024regulationofraf pages 1-3): Russell Spencer-Smith and Deborah K. Morrison. Regulation of raf family kinases: new insights from recent structural and biochemical studies. Biochemical Society Transactions, 52:1061-1069, May 2024. URL: https://doi.org/10.1042/bst20230552, doi:10.1042/bst20230552. This article has 19 citations and is from a peer-reviewed journal.
(bahar2023targetingtherasrafmapk pages 1-2): Md Entaz Bahar, Hyun Joon Kim, and D. Kim. Targeting the ras/raf/mapk pathway for cancer therapy: from mechanism to clinical studies. Signal Transduction and Targeted Therapy, Dec 2023. URL: https://doi.org/10.1038/s41392-023-01705-z, doi:10.1038/s41392-023-01705-z. This article has 976 citations and is from a peer-reviewed journal.
(spencersmith2024regulationofraf media 4220244e): Russell Spencer-Smith and Deborah K. Morrison. Regulation of raf family kinases: new insights from recent structural and biochemical studies. Biochemical Society Transactions, 52:1061-1069, May 2024. URL: https://doi.org/10.1042/bst20230552, doi:10.1042/bst20230552. This article has 19 citations and is from a peer-reviewed journal.
(spencersmith2024regulationofraf media 1fe62c33): Russell Spencer-Smith and Deborah K. Morrison. Regulation of raf family kinases: new insights from recent structural and biochemical studies. Biochemical Society Transactions, 52:1061-1069, May 2024. URL: https://doi.org/10.1042/bst20230552, doi:10.1042/bst20230552. This article has 19 citations and is from a peer-reviewed journal.
(adamopoulos2024rafandmek pages 2-4): Christos Adamopoulos, Kostas A. Papavassiliou, Poulikos I. Poulikakos, and Athanasios G. Papavassiliou. Raf and mek inhibitors in non-small cell lung cancer. International Journal of Molecular Sciences, 25:4633, Apr 2024. URL: https://doi.org/10.3390/ijms25094633, doi:10.3390/ijms25094633. This article has 18 citations.
(rauch2016differentiallocalizationof pages 1-2): J. Rauch, D. Vandamme, B. Mack, B. McCann, N. Volinsky, A. Blanco, O. Gires, and W. Kolch. Differential localization of a-raf regulates mst2-mediated apoptosis during epithelial differentiation. Cell Death & Differentiation, 23:1283-1295, Feb 2016. URL: https://doi.org/10.1038/cdd.2016.2, doi:10.1038/cdd.2016.2. This article has 32 citations and is from a domain leading peer-reviewed journal.
(su2022arafproteinkinase pages 3-5): Wenjing Su, Radha Mukherjee, Rona Yaeger, Jieun Son, Jianing Xu, Na Na, Neilawattie Merna Timaul, Jaclyn Hechtman, Viktoriya Paroder, Mika Lin, Marissa Mattar, Juan Qiu, Qing Chang, Huiyong Zhao, Jonathan Zhang, Megan Little, Yuta Adachi, Sae-Won Han, Barry S. Taylor, Hiromichi Ebi, Omar Abdel-Wahab, Elisa de Stanchina, Charles M. Rudin, Pasi A. Jänne, Frank McCormick, Zhan Yao, and Neal Rosen. Araf protein kinase activates ras by antagonizing its binding to rasgap nf1. Molecular Cell, 82:2443-2457.e7, Jul 2022. URL: https://doi.org/10.1016/j.molcel.2022.04.034, doi:10.1016/j.molcel.2022.04.034. This article has 28 citations and is from a highest quality peer-reviewed journal.
(su2022arafproteinkinase pages 7-8): Wenjing Su, Radha Mukherjee, Rona Yaeger, Jieun Son, Jianing Xu, Na Na, Neilawattie Merna Timaul, Jaclyn Hechtman, Viktoriya Paroder, Mika Lin, Marissa Mattar, Juan Qiu, Qing Chang, Huiyong Zhao, Jonathan Zhang, Megan Little, Yuta Adachi, Sae-Won Han, Barry S. Taylor, Hiromichi Ebi, Omar Abdel-Wahab, Elisa de Stanchina, Charles M. Rudin, Pasi A. Jänne, Frank McCormick, Zhan Yao, and Neal Rosen. Araf protein kinase activates ras by antagonizing its binding to rasgap nf1. Molecular Cell, 82:2443-2457.e7, Jul 2022. URL: https://doi.org/10.1016/j.molcel.2022.04.034, doi:10.1016/j.molcel.2022.04.034. This article has 28 citations and is from a highest quality peer-reviewed journal.
(silverman1989expressionofc‐raf‐1 pages 1-2): Jeffrey A. Silverman, Joanne Zurlo, Michael A. Watson, and James D. Yager. Expression of c‐raf‐1 and a‐raf‐1 during regeneration of rat liver following surgical partial hepatectomy. Molecular Carcinogenesis, 2:63-67, Jan 1989. URL: https://doi.org/10.1002/mc.2940020203, doi:10.1002/mc.2940020203. This article has 14 citations and is from a peer-reviewed journal.
(silverman1989expressionofc‐raf‐1 pages 2-3): Jeffrey A. Silverman, Joanne Zurlo, Michael A. Watson, and James D. Yager. Expression of c‐raf‐1 and a‐raf‐1 during regeneration of rat liver following surgical partial hepatectomy. Molecular Carcinogenesis, 2:63-67, Jan 1989. URL: https://doi.org/10.1002/mc.2940020203, doi:10.1002/mc.2940020203. This article has 14 citations and is from a peer-reviewed journal.
(wang2020alterationsofglucose pages 6-7): Maolin Wang, Xiaofeng Pu, Bimin Feng, Qingze Fan, Yan Dai, Yue Chen, Ying Li, Liang Liu, Shousong Cao, and Guojun Wang. Alterations of glucose uptake and protein expression related to the insulin signaling pathway in the brain of phenobarbital-addictive rats by 18f-fdg pet/ct and proteomic analysis. Oct 2020. URL: https://doi.org/10.1021/acs.jproteome.0c00703, doi:10.1021/acs.jproteome.0c00703. This article has 5 citations and is from a peer-reviewed journal.
(spencersmith2024regulationofraf pages 6-7): Russell Spencer-Smith and Deborah K. Morrison. Regulation of raf family kinases: new insights from recent structural and biochemical studies. Biochemical Society Transactions, 52:1061-1069, May 2024. URL: https://doi.org/10.1042/bst20230552, doi:10.1042/bst20230552. This article has 19 citations and is from a peer-reviewed journal.
(adamopoulos2024rafandmek pages 1-2): Christos Adamopoulos, Kostas A. Papavassiliou, Poulikos I. Poulikakos, and Athanasios G. Papavassiliou. Raf and mek inhibitors in non-small cell lung cancer. International Journal of Molecular Sciences, 25:4633, Apr 2024. URL: https://doi.org/10.3390/ijms25094633, doi:10.3390/ijms25094633. This article has 18 citations.
(NCT06362694 chunk 1): Ernest Dzhelialov. Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy. Saint Petersburg State University, Russia. 2024. ClinicalTrials.gov Identifier: NCT06362694
(NCT05525273 chunk 1): Eva Marie Erfurth, MD, PhD. Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma. Eva Marie Erfurth, MD, PhD. 2023. ClinicalTrials.gov Identifier: NCT05525273
(NCT04324112 chunk 1): Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL. National Cancer Institute (NCI). 2020. ClinicalTrials.gov Identifier: NCT04324112
(NCT04903119 chunk 1): Rina Plattner. Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma. Rina Plattner. 2022. ClinicalTrials.gov Identifier: NCT04903119
(NCT06262919 chunk 1): Special Drug Use-results Surveillance of Tafinlar/Mekinist. Novartis Pharmaceuticals. 2024. ClinicalTrials.gov Identifier: NCT06262919
(bahar2023targetingtherasrafmapk pages 16-17): Md Entaz Bahar, Hyun Joon Kim, and D. Kim. Targeting the ras/raf/mapk pathway for cancer therapy: from mechanism to clinical studies. Signal Transduction and Targeted Therapy, Dec 2023. URL: https://doi.org/10.1038/s41392-023-01705-z, doi:10.1038/s41392-023-01705-z. This article has 976 citations and is from a peer-reviewed journal.
(adamopoulos2024rafandmek pages 4-5): Christos Adamopoulos, Kostas A. Papavassiliou, Poulikos I. Poulikakos, and Athanasios G. Papavassiliou. Raf and mek inhibitors in non-small cell lung cancer. International Journal of Molecular Sciences, 25:4633, Apr 2024. URL: https://doi.org/10.3390/ijms25094633, doi:10.3390/ijms25094633. This article has 18 citations.
(OpenTargets Search: -ARAF): Open Targets Query (-ARAF, 6 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.